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Collectrin (Tmem27 or Nx-17) was first identified in a screen for genes that are upregulated during the hypertro-
phic phase after renal mass ablation, a model of chronic kid-
ney disease.1 The protein product is a 222-aa transmembrane 
glycoprotein that shares ≈50% sequence identity with angio-
tensin-converting enzyme 2. Unlike angiotensin-converting 
enzyme 2, collectrin lacks any catalytic domain.2 Collectrin 
is highly conserved among species, sharing >80% identity 
between mice, rats, and humans. Collectrin has a discrete tis-
sue distribution, with the highest expression levels in the prox-
imal tubule and collecting duct of the adult kidney, followed 
by pancreatic B cells, liver, intestinal epithelial cells, and the 
retina. Taken together, these data suggest that collectrin has 
distinct effects specific to its tissue localization. In support, 
in vitro and in vivo studies reveal that collectrin is involved in 
insulin secretion3 and islet mass in the pancreas.4 In the kidney, 
we and others have demonstrated that deletion of collectrin 
results in severe generalized urinary amino acid wasting as a 
result of reduced expression of neutral and cationic amino acid 
transporters in the plasma membrane of the proximal tubule 
brush border.5,6 These studies illustrate a role for collectrin as 
a chaperone for amino acid transporters. The mechanism by 
which collectrin mediates amino acid transporter trafficking 
is thought to be its binding with the SNARE complex. In the 
pancreas, collectrin facilitates SNARE complex formation by 
interacting with snapin, a synaptosomal-associated protein.3 
Background—Collectrin is an orphan member of the renin-angiotensin system and is a homolog of angiotensin-converting 
enzyme 2, sharing ≈50% sequence identity. Unlike angiotensin-converting enzyme 2, collectrin lacks any catalytic domain. 
Collectrin has been shown to function as a chaperone of amino acid transporters. In rodents, the renal expression of 
collectrin is increased after subtotal nephrectomy and during high-salt feeding, raising the question of whether collectrin 
has any direct role in blood pressure regulation.
Methods and Results—Using a susceptible genetic background, we demonstrate that deletion of collectrin results in 
hypertension, exaggerated salt sensitivity, and impaired pressure natriuresis. Collectrin knockout mice display impaired 
endothelium-dependent vasorelaxation that is associated with vascular remodeling, endothelial nitric oxide synthase 
uncoupling, decreased nitric oxide production, and increased superoxide generation. Treatment with Tempol, a superoxide 
scavenger, attenuates the augmented sodium sensitivity in collectrin knockout mice. We report for the first time that 
collectrin is expressed in endothelial cells. Furthermore, collectrin directly regulates l-arginine uptake and plasma 
membrane levels of CAT1 and y+LAT1 amino acid transporters in endothelial cells. Treatment with l-arginine modestly 
lowers blood pressure of collectrin knockout mice.
Conclusions—Collectrin is a consequential link between the transport of l-arginine and endothelial nitric oxide synthase 
uncoupling in hypertension.   (Circulation. 2013;128:1770-1780.)
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In the collecting duct, collectrin interacts with snapin, SNAP-
23, syntaxin-4, and VAMP-2.7
As a member of the angiotensin-converting enzyme fam-
ily, how collectrin is functionally integrated in the context 
of blood pressure (BP) regulation is not known. The collec-
trin gene is located on the X chromosome, where loci have 
been linked to hypertension in both humans and rats.8,9 The 
expression of collectrin in the kidney is upregulated after 5/6 
nephrectomy1 and during salt-sensitive hypertension,7 but the 
cause or effect remains to be established. Interestingly, in rat 
models of salt-sensitive hypertension, loci on the X chromo-
some have also been linked to hypertension10 and hypertensive 
nephrosclerosis.11
Taken together, the evidence suggests that collectrin plays 
a role in BP regulation. We set out to determine the role of 
collectrin in BP homeostasis in normal- and high-salt states. 
On a mixed genetic background, we found no BP difference 
between collectrin knockout (KO) and wild-type (WT) mice.7 
Because of the possibility that the genetic background masks 
any BP effect commonly observed in many mouse models of 
cardiovascular disease and hypertension, we backcrossed the 
collectrin-null mutation on the 129S6 strain that is susceptible 
to the development of hypertension and salt sensitivity.12,13 
Here, on the 129S6 background, we show that collectrin is a 
determining factor in the development of hypertension in con-
ditions in which the l-arginine/nitric oxide (NO)/superoxide 
pathway is altered.
Methods
Animals
Mice deficient of collectrin were generated by homologous recom-
bination in embryonic stem cells, as previously reported.5 To gen-
erate the inbred 129S6 collectrin KO mouse line, the null mutation 
was backcrossed onto the 129S6 background for >14 generations. 
The collectrin gene is located on the X chromosome; thus, WT lit-
termates cannot be obtained for female KOs. Therefore, only male 
KO mice and their WT littermates were used for all studies described 
here. Animals were bred and maintained under local and National 
Institutes of Health guidelines.
Radiotelemetric BP Monitoring In Vivo
With the exception of BP measurement after subtotal nephrectomy, 
all BPs were measured in conscious mice under unrestrained condi-
tions by radiotelemetry. Radiotelemetric units were implanted as pre-
viously described.14 See the online-only Data Supplement for more 
information.
Measurement of Tissue Superoxide and NO Levels
For superoxide, the method was modified from previous studies.15,16 
Briefly, Krebs-HEPES buffer (in mmol/L: 99.0 NaCl, 4.69 KCl, 1.2 
MgSO4, 25.0 NaHCO3, 1.03 KHPO4, 5.6 D(+) glucose, 20 Na HEPES, 
2.5 CaCl2, pH 7.2–7.4 with 1N HCl) was oxygenated for 15 minutes 
in a water bath at 37°C. A 3- to 5-mg piece of kidney cortical tissue 
was placed in oxygenated buffer and incubated for 30 minutes in the 
water bath at 37°C and then placed into 5-µmol/L Lucigenin (9,9’-Bis-
N-methylacridinium nitrate, Sigma; M8010) solution prepared in 
Krebs-HEPES buffer for 5 minutes. Then, luminescence counts were 
taken 5 times for 1 minute each, averaged, and corrected for baseline 
(5 µmol/L Lucigenin in Krebs-HEPES buffer measured 5 times for 1 
minute and averaged). Tissue was dried in the dry block at 60°C to 
70°C overnight. Results are expressed as counts per 1 mg dry tissue. 
NO activity was measured by conversion of [3H]arginine to [3H]citrul-
line via an NO assay kit (R&D Systems), as previously described.17
Endothelium-Dependent and -Independent 
Relaxation Assays
Vasoreactivity measurements were performed as previously 
described.18 See the online-only Data Supplement for additional 
information.
Isolation of Mouse Pulmonary Endothelial Cells
Primary lung endothelial cells (ECs) were isolated as previously 
described17 and were used for subsequent l-arginine uptake assay. 
Details are given in the online-only Data Supplement.
[3H]l-Arginine Uptake
[3H]l-arginine uptake assay was performed following a previously 
published protocol.19 ECs were grown in 24-well plates to near con-
fluence, washed in Dulbecco PBS, and incubated in Na-free uptake 
buffer for 5 minutes at 37°C. Some of the wells were then incubated 
with 0.5 mL per well of either warmed 50 μmol/L l-arginine+100 
nmol/L [3H]l-arginine or warmed 20 mmol/L l-arginine+100 nmol/L 
[3H]l-arginine for 1 minute. The wells were then washed 4 times with 
ice-cold Na-free uptake buffer, and the cells were solubilized in 0.5 
mL 0.2% SDS and 0.2N NaOH. Two 0.2-mL aliquots were counted 
with a Beckman Coulter scintillation counter, and 5 mL Ultama Gold 
LLT scintillation fluid (Perkin-Elmer) and two 25-μL aliquots were 
assayed for protein concentration with the Pierce BCA Protein Assay 
Kit (Thermo Scientific).
Statistics
Data are expressed as mean±SE. Statistical calculations were done 
with commercially available software packages (Minitab, Inc. 
and NCSS). The Student t test was used for comparisons between 
2 groups unless otherwise stated. Differences between matched 
samples were analyzed by a paired t test. ANOVA was performed 
to test for significant overall group differences when there were >2 
groups. Endothelium-dependent and -independent relaxation assays 
were analyzed with GraphPad Prism software. Values of P<0.05 were 
considered statistically significant. P values were 2 sided. Given the 
nature of the study, there was no adjustment for multiple comparisons.
Results
Deletion of Collectrin Causes Hypertension, 
Augmented Salt Sensitivity, and Attenuated 
Pressure Natriuresis Response
By radiotelemetry monitoring, collectrin KO mice have 
normal diurnal variation (Figure IA in the online-only Data 
Supplement) but significantly elevated systolic BP (SBP; 
Figure 1A) and mean arterial pressure (Figure IB in the 
online-only Data Supplement) during both light and dark 
cycles. The average SBP over a 14-day period at baseline (on 
normal-salt diet) was ≈ 9 mm Hg higher in collectrin KO mice 
(Figure 1B) and is associated with a significant increase in 
heart mass (Figure 1A) that correlates well with SBP (Figure 
IC in the online-only Data Supplement), suggesting increased 
pressure load inducing cardiac remodeling. Because the 
expression of collectrin is upregulated in rodent models of 
chronic kidney disease and salt-sensitive hypertension, we 
assessed the effect of collectrin on BP in these models. After 
subtotal nephrectomy, collectrin KO mice had significant 
mortality within 2 weeks (Figure IIA in the online-only Data 
Supplement). However, after uninephrectomy, collectrin KO 
mice had normal survival but developed much more severe 
hypertension than WT mice (Figure IIB in the online-only 
Data Supplement). We next determined the effect of collectrin 
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on salt sensitivity by feeding mice a high-salt diet (HSD; 6% 
NaCl) for 2 weeks. Compared with WT mice, which displayed 
a ≈8-mm Hg increase in SBP from normal-salt diet to HSD, 
collectrin KO mice displayed ≈15-mm Hg increase in SBP 
(Figure 1B). In addition, collectrin KO mice had a significantly 
lower urinary sodium excretion by the third day (acute phase) 
of HSD (Figure 1B). There were no significant differences in 
food or NaCl consumption between the 2 groups. However, 
there was a transient increase in water intake and a trend for 
increased urine volume in collectrin KO mice on day 1 (Table). 
These findings demonstrate an attenuated pressure natriuresis 
response in collectrin KO mice. The significant increase in BP 
in collectrin KO mice after HSD was also accompanied by 
evidence of end-organ damage, including increased cardiac 
fibrosis (Figure 2A), glomerular mesangial hypercellularity, 
and thickened renal vascular walls (Figure 2B).
Deletion of Collectrin Results in Altered Balance of 
NO and Superoxide
To begin to understand the mechanism contributing to hyper-
tension and salt sensitivity in collectrin KO mice, we examined 
whole-kidney plasma membrane expression of renal epithe-
lial salt transporters and channels, including αENaC, NHE3, 
NKCC, Na-K-ATPase, and NaPi2, but found no differences 
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Figure 1. Deletion of collectrin causes hypertension, augmented salt sensitivity, and attenuated pressure natriuresis response. A, Left, 
average systolic blood pressure (SBP) of wild-type (WT) and knockout (KO) mice during 12-hour periods of light and dark cycles over  
14 days. *P≤0.001. Right, Heart weight/body weight ratios (*P=0.016). B, Top left, Average SBP over 14 days of normal-salt diet and 
high-salt diet (HSD). *P<0.02. Top right, The change in SBP from a normal-salt diet to an HSD was higher in KO mice (P=0.01). Bottom 
left, Daily SBP at baseline (days 9–14) and after HSD (start and days 1–14). Bottom right, Average daily urinary sodium excretions during 
the first 3 days (acute phase) of HSD are significantly lower in the KO mice on the third day (P=0.018). Values are expressed as mean±SE; 
n≥6 all studies.
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(Figure ID in the online-only Data Supplement). There was 
no difference in baseline plasma renin concentration (P=0.40; 
Figure IE in the online-only Data Supplement). There were 
also no differences in mRNA expression levels of angioten-
sin-converting enzyme 2 or Mas receptor in the renal cortex 
by real-time reverse transcriptase–polymerase chain reac-
tion (Figure IF in the online-only Data Supplement). We next 
measured urinary 8-isoprostane F2α and nitrate/nitrite levels, 
which are indexes of superoxide (O2∙ −) and NO generation, 
respectively, during the first 3 days of HSD. Collectrin KO 
mice excreted more than twice the levels of 8-isoprostane F2α 
and 40% less nitrates/nitrites compared with WT (Figure 3A). 
These data suggest that augmented renal O2∙ − generation or 
impaired renal NO production contributes to altered BP regu-
lation and pressure natriuresis in collectrin KO mice.
Hypertension and salt sensitivity are pathological condi-
tions commonly associated with a state of endothelial NO 
synthase (eNOS) uncoupling.20–23 In the active form, eNOS 
is a homodimer that oxidizes l-arginine to l-citrulline and 
NO. Various perturbations, including decreased availability of 
l-arginine, can lead to the uncoupling of eNOS to the mono-
meric form that generates O2∙ − instead of NO.24,25 We next 
compared baseline levels of eNOS dimer and monomer in the 
aorta and kidney cortex and medulla. In these tissues, eNOS 
dimer and dimer/monomer ratios were significantly lower 
in collectrin KO mice compared with WT (Figure 3B), sug-
gesting that there is an altered balance of active and inactive 
eNOS in collectrin KO mice that favors a state of increased 
O2∙ − generation and reduced NO synthesis. In support, we 
found a significant increase in baseline O2∙ − and a significant 
decrease in baseline NO levels in whole-kidney tissues in KO 
mice (Figure 3C). We next determined whether the superox-
ide scavenger Tempol would correct the augmented sodium 
sensitivity in collectrin KO mice. Treatment with Tempol (via 
osmotic pump) resulted in a mild but statistically insignificant 
lowering of BP in both WT and KO mice at baseline. Tempol 
did not attenuate salt sensitivity in WT mice. However, 
Tempol significantly attenuated the increase in BP in collec-
trin KO during high-salt feeding (Figure 3D), resulting in a 
similar change in BP from normal salt to high salt between 
WT and KO mice (Figure 3E). These data suggest that the 
mechanism for augmented sodium sensitivity in collectrin KO 
mice is mediated in part by superoxide.
Loss of Collectrin Causes Impairment in 
Endothelium-Dependent Vasorelaxation
The expression of collectrin in ECs has not been previously 
reported. Here, we show that collectrin is expressed in ECs in 
WT
A
B
KO
WT KO
Figure 2. Evidence of end-organ damage in collectrin knockout 
(KO) mice. A, Masson trichrome staining of cross sections of 
cardiac ventricles (at ×20) from 3 mice in each group after a 
high-salt diet showing increased fibrosis in KO mice. B, Renal 
histology by light microscopy. Hematoxylin and eosin stain 
demonstrates normal glomeruli (arrowheads) and renal interlobar 
artery in wild-type (WT) mice but diffuse glomerular mesangial 
hypercellularity and thickened vascular smooth muscle wall of 
interlobar artery in KO mice. Magnification: top, ×20; glomeruli 
insets, ×40; and bottom, ×40.
Table.  Metabolic Cage Studies During the First 3 Days on a High-Salt Diet
Day 1 Day 2 Day 3
WT (n=6) KO (n=6) WT (n=6) KO (n=6) WT (n=6) KO (n=6)
Body weight, g 24. 2±1.6 24.9±0.92 23.6±1.1 24.9±0.92 23.9±1.0 24.6±0.67
Percent of initial body weight 92.4±0.01 92.9±0.01 90.6±0.01 92.7±0.01 91.5 ± 0.01 91.5±0.01
Water intake, g 6.1±0.76 10.3±0.91* 9.9±1.45 12.4±0.74 10.4±1.15 11.4±1.76
Food intake, g 4.9±0.98 5.2±0.37 5.7±0.52 5.8±0.31 5.9±0.57 6.3±0.67
NaCl intake, g 0.30±0.06 0.31±0.02 0.34±0.03 0.35±0.02 0.35±0.03 0.38±0 0.04
Urine volume, mL 4.8±0.61 6.1±0.31 6.7±0.85 7.1±0.60 5.6±0.53 5.8±0.64
Fecal weight, g 0.60±0.05 0.73±0.13 0.81±0.15 0.86±0.09 0.88±0.83 0.83±0.14
Data are expressed as mean±SE. The initial body weight of WT mice was 26.2±1.4 g and of KO mice was 26.9±0.88 g (P=NS). KO indicates knockout; 
and WT, wild-type.
*P=0.03.
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Figure 3. Deletion of collectrin results in altered balance of nitric oxide and superoxide. A, Comparison of urinary 8-isoprostane F2α and 
nitrate/nitrite levels averaged over the first 3 days of a high-salt diet: 8-isoprostane F2α, P=0.008; nitrates/nitrites, P=0.03, n≥4 each. 
B, Comparison of active (dimer) and inactive (monomer) forms of endothelial nitric oxide synthase (eNOS). Left, Immunoblot of aorta and 
kidney cortex and medulla at baseline. Right, Densities of eNOS dimer and monomer bands normalized to tubulin. #P≤0.04; ΨP≤0.002. 
C, Baseline renal tissue levels of superoxide and nitric oxide. Left, Superoxide levels (*P=0.02). Right, Nitric oxide levels (*P=0.025). 
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the thoracodorsal and renal resistance vessels (Figure 4A–4E 
and Figure IIIA and IIIB in the online-only Data Supplement. 
We next queried whether loss of collectrin could lead to endo-
thelial dysfunction, and we compared the resistance vessel 
relaxation capacity of third-order mesenteric arteries between 
WT and KO mice fed a normal-salt diet. Collectrin KO mice 
have severely impaired endothelium-dependent relaxation of 
third-order mesenteric arteries in response to acetylcholine 
(Figure 4F). Very similar differences in response to acetyl-
choline were also observed in thoracodorsal arteries between 
the 2 groups (Figure 4F). Transmission electron microscopy 
revealed that the thoracodorsal arteries of collectrin KO 
mice are markedly remodeled, with vacuolization of ECs 
and a hypertrophic and disorganized smooth muscle layer 
(Figure 4G). To determine whether the vascular smooth mus-
cle cells play a role in the impaired vasorelaxation in collec-
trin KO mice, we performed an endothelium-independent 
relaxation assay using sodium nitroprusside. As shown in 
Figure 4H, WT and collectrin KO mesenteric and thoracodor-
sal arteries had virtually identical vasodilatory responses to 
sodium nitroprusside, suggesting that the impaired vasodila-
tion in the collectrin KO mice is primarily dependent on the 
endothelium.
Collectrin Regulates l-Arginine Uptake and Plasma 
Membrane Expression of l-Arginine Amino Acid 
Transporters in ECs
Our data raise the central question of whether collectrin regu-
lates BP through its role in amino acid transport, particularly 
l-arginine. In this regard, KO mice have altered BP homeosta-
sis, which is associated with abnormal NO synthesis and O2∙ −
generation. In several cell types, including the ECs and renal 
epithelium, the synthesis of NO requires the de novo import 
of extracellular l-arginine.26–28 l-Arginine transport into cells 
is mediated by different classes of amino acid transporters that 
are defined by their ion dependency, substrate specificity, and 
relative affinity.29,30 In ECs, system y+, a sodium-independent 
system, accounts for ≈60% of l-arginine transport, and sys-
tem y+L, a sodium-dependent system, accounts for ≈40% 
of l-arginine transport.26,31,32 System y+ selectively mediates 
the cellular transport and exchange of cationic amino acids, 
including l-arginine, whereas system y+L transports and 
mediates the exchange of both cationic and neutral amino 
acids.26,28 Endothelium-dependent relaxation has been shown 
to be impaired in a patient with l-arginine deficiency who was 
shown to be a compound heterozygote for 2 mutations in the 
SLC7A7 gene that encodes for the y+LAT1 amino acid trans-
porter. The patient’s endothelium-dependent relaxation was 
corrected with l-arginine infusion.33 Thus, a defect in l-argi-
nine uptake may lead to endothelial dysfunction. To determine 
whether collectrin-deficient ECs have impaired l-arginine 
uptake, we isolated primary ECs from WT and collectrin KO 
mice from the pulmonary artery using fluorescence-activated 
cell sorting.17 Collectrin KO ECs display significantly lower 
[3H]l-arginine uptake than WT ECs (Figure 5A). To rule out 
the possibility that altered structural integrity of collectrin-
deficient ECs (Figure 4G) influenced l-arginine uptake and to 
demonstrate a direct cause and effect of collectrin on l-argi-
nine uptake, we used a primary human coronary EC line and 
successfully overexpressed collectrin (Figure 5B). Human 
coronary ECs overexpressing collectrin have significantly 
higher levels of [3H]l-arginine uptake compared with control 
cells (Figure 5B).
We previously reported that collectrin KO mice have gen-
eralized urinary amino acid wasting and decreased protein 
expression of the apical amino acid transporters in plasma 
membrane fractions of the renal proximal tubules, suggest-
ing that collectrin is a chaperone that mediates the traffick-
ing of amino acid transporters to the plasma membrane.5 We 
next examined whether collectrin affects the expression of the 
y+ (CAT1) and y+L (y+LAT1) amino acid transporter systems 
that are known to regulate l-arginine transport in ECs.34 We 
demonstrate that knockdown of collectrin results in a signifi-
cant decrease in expression of CAT1 and y+LAT1 transport-
ers in human coronary EC plasma membrane fractions and 
decreased eNOS dimerization (Figure 5C). Conversely, over-
expression of collectrin significantly increases the expression 
levels of these transporters and increases eNOS dimerization 
115
120
125
130
135
140
145
150
155
160
165
D E
Normal Salt High Salt
Sy
st
ol
ic
 B
lo
od
 P
re
ss
ur
e 
(m
m
 H
g)
WT
WT + Tempol
KO
KO + Tempol
#
ψ
ψ
ψ
δ
ψ
0
2
4
6
8
10
12
14
16
18
20 ∗ ∗
Without Tempol With Tempol
C
ha
ng
e 
in
 S
ys
to
lic
 B
P 
(m
m
 H
g)
w
ith
 H
ig
h 
Sa
lt 
D
ie
t
WT
KO
Figure 3. (continued) D, Tempol attenuates the augmented sodium sensitivity in collectrin knockout (KO) mice. Normal salt: #P<0.001, 
ΨP=0.02. High salt: δP=0.01, ΨP≤0.02 (n≥6 in each group). E, Tempol decreases change in blood pressure (BP) in KO mice after a high-
salt diet. Change in systolic BP: for wild type (WT)+Tempol vs KO+Tempol, P=0.52; for KO vs KO+Tempol, *P≤0.04. Mice without Tempol 
treatment are the same mice represented in Figure 1B.
 by guest on February 12, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
1776  Circulation  October 15, 2013
(Figure 5D). We also examined whether loss of collectrin also 
affects kidney plasma membrane expression of the y+LAT1 
transporter that is localized to the basolateral membrane in 
renal epithelial cells.35 We found a significant decrease in the 
expression of the y+LAT1 transporter in whole-kidney plasma 
membrane fractions from KO mice (Figure IV in the online-
only Data Supplement). We next queried whether supplemen-
tation with l-arginine would ameliorate or decrease BP in 
collectrin KO mice. We administered l-arginine in drinking 
water (50 mg∙kg−1∙d−1). As demonstrated in Figure 5E, by the 
end of 1 week of treatment with l-arginine, a modest but sig-
nificant decrease in SBP in collectrin KO mice was observed. 
There was no further decrease in SBP beyond 1 week of 
l-arginine treatment.
Discussion
Collectrin is an “orphan” member of the renin-angiotensin 
system with a previously unrecognized role in cardiovascu-
lar and renal physiology. We demonstrate that loss of collec-
trin results in hypertension, altered pressure natriuresis, 
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and superoxide-dependent augmented salt sensitivity. We 
further demonstrate that deletion of collectrin results in 
endothelial dysfunction, which is associated with eNOS 
uncoupling, increased O2∙ − production, and decreased NO 
availability, likely as a result of impaired cellular uptake of 
l-arginine substrate. Our data suggest that collectrin plays 
a protective role against conditions that predispose to the 
hypertensive state by maintaining a balance of NO and 
O2∙ − through its role in facilitating the cellular uptake of 
l-arginine. It is worth noting that we previously reported 
Figure 5. Collectrin regulates l-arginine (Arg) uptake and plasma membrane expression of l-arginine amino acid transporters in endothelial 
cells (ECs). A, Primary pulmonary ECs from knockout (KO) mice have significantly lower [3H]l-arginine uptake (*P=0.01; n=6 separate wells 
each group done in duplicates). B, Top, immunoblot of collectrin in primary human coronary ECs (HCECs). Left, Untransfected; middle, 
empty pBK-cytomegalovirus (CMV) vector; right, transfected with pBK-CMV collectrin expression vector. Bottom, [3H]l-arginine uptake in 
primary HCECs transfected with empty (control) or collectrin expression vector (*P=0.003; n=6 separate transfection experiments performed 
in duplicates). C and D, Immunoblots comparing the expression of collectrin and the l-arginine amino acid transporters CAT1 and y+LAT1 in 
plasma membrane fractions of primary HCECs. C, Top, Control vs collectrin knockdown conditions with siRNA. Middle, Relative densities 
normalized to tubulin (*P<0.05). C, Bottom, Immunoblot of endothelial nitric oxide synthase (eNOS) dimers and monomers. D, Top, Control 
vs collectrin overexpression conditions; middle, relative densities normalized to tubulin (*P≤0.04); bottom, immunoblot of eNOS dimers and 
monomers. E, Blood pressure (BP) response to treatment with l-arginine (P=0.008 by paired analysis; n=5).
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that collectrin KO mice have normal development, are able 
to compensate for renal wasting of amino acids by increased 
liver synthesis of nonessential amino acids, and are able to 
maintain normal serum levels of all amino acids, including 
l-arginine.5,36 Thus, the effect of collectrin deficiency on BP 
is unlikely from renal wasting of l-arginine per se. Our data 
suggest that collectrin may regulate BP specifically through 
its role chaperoning l-arginine transporters expressed in 
ECs and possibly in renal epithelial cells for the intracellu-
lar uptake of l-arginine. The partial BP lowering response to 
l-arginine infusion supports the notion of competitive inhi-
bition of l-arginine uptake by other extracellular cationic 
amino acids such as lysine.28 Accordingly, administration 
of l-arginine could overwhelm the competitive inhibition 
of extracellular lysine. However, the lack of normalization 
of BP by l-arginine infusion implicates a severe deficit in 
the functional activity of the CAT1 and y+L system trans-
porters resulting from their diminished plasma membrane 
expression. It is also possible that collectrin interacts with 
other machinery that regulates eNOS enzymatic activity. In 
this regard, endothelial caveolae containing caveolins are 
important in determining intracellular localization of eNOS 
and enzymatic activity.37 Interestingly, endothelial caveolae 
contain some members of the SNARE complex38 with which 
collectrin interacts.3,7 Our study suggests that the altered 
balance of NO and O2∙ − plays a partial role in the elevation 
of BP and augmented sodium sensitivity in collectrin KO 
mice. It is likely that other yet-to-be-determined mecha-
nisms are also involved.
Our findings are consistent with the clinical observation 
that mutations resulting in dysfunction of the y+LAT1 trans-
porter cause impaired endothelium-dependent relaxation.33 
The reduction in l-arginine transport via the y+L system has 
also been observed in hypertension in both humans and ani-
mals.39,40 In addition, the Dahl salt-sensitive versus salt-resis-
tant rats are a classic genetic model that links salt-sensitive 
hypertension with alteration in the O2∙ −/NO states. Dahl salt-
sensitive rats consuming an HSD exhibit increased urinary 
excretion of 8-isoprostane, an index of oxidative stress, and 
significant reductions of kidney and aorta eNOS.41 Infusion 
of l-arginine into the renal medullary interstitium of Dahl 
salt-sensitive rats prevents the development of hypertension 
during high-salt feeding.42 The genetic basis for their pheno-
type is unclear. Our studies demonstrate that collectrin-defi-
cient mice have a phenotype very similar to that of the Dahl 
salt-sensitive rats.
Although an 8- to 9-mm Hg baseline increase in SBP in 
collectrin KO may be viewed as modest, it is worth noting that 
this has significant physiological effects because collectrin 
KO mice have increased heart mass and vascular remodeling 
at baseline. Results from numerous clinical trials show that 
even a 2- to 3-mm Hg increase in SBP confers a significant 
increase in cardiovascular disease risks. In addition, collectrin 
KO mice on an HSD have a ≈15-mm Hg higher SBP than WT 
mice on an HSD, along with increased cardiac fibrosis and 
mesangial hypercellularity in the glomerulus. This augmented 
sodium sensitivity is mediated in part by superoxide.
As mentioned, our previous study using mice on a mixed 
genetic background showed that collectrin KO mice have a 
basal BP similar to that of WT mice, and they did not exhibit 
sodium sensitivity.7 This demonstrates that the role of collec-
trin on BP regulation in normal and pathophysiologic states 
is dependent on the genetic background. The dependency on 
a susceptible genetic milieu is similar to many rodent mod-
els of human diseases. For example, the Ace2 and the fre-
quently used Apoe KO mouse models require the C57BL/6 
strain for the development of hypertension14 and abdominal 
aortic atherosclerotic disease,43,44 respectively. The require-
ment of a proper genetic background does not diminish the 
significance of the effect of a gene but highlights the involve-
ment of epigenetic or multigenic effects. In essential or salt-
sensitive hypertension, the pathogenesis is likely mediated by 
small effects of many genes rather than a rare large effect of 
1 single gene.
It is worth noting that our studies were conducted with male 
mice because collectrin is on the X chromosome and there-
fore WT littermates cannot be obtained for female KO mice. 
It remains to be determined whether collectrin has the same 
effect on BP and salt-sensitive hypertension in female mice. 
Interestingly, in the Sabra rat model of salt-sensitive hyper-
tension, loci on the X chromosome have also been linked to 
salt sensitivity in females but not in males.10 Because of the 
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discrepancy of the position of the rat microsatellite mark-
ers, which differ significantly between 2003 and 2012, it is 
unclear whether collectrin lies within any of these loci. In 
humans, it is not known whether there are any loci on the X 
chromosome that contribute to sex-linked differences in heri-
tability of hypertension because until recently genome-wide 
association studies largely excluded X chromosome variants 
from analyses.
Although our results may suggest that the endothelial dys-
function in collectrin KO mice could contribute to their hyper-
tension, they are interpreted with caution because impairment 
in endothelial function may also be a consequence of hyper-
tension that induces remodeling of the endothelium. We can-
not rule out possible effects of collectrin on circulating or 
other vasoactive mediators released by the endothelium such 
as endothelium-derived hyperpolarizing factor, prostacyclin, 
and epoxyeicosatrienoic acids. Endothelium-specific deletion 
of collectrin will provide direct proof of causality and will be 
a focus of future studies.
Our studies raise the key question of which specific collec-
trin-expressing cell plays a major role in BP regulation. 
Guyton and Coleman45 advanced the paradigm that the sub-
stantial capacity of the kidney for sodium excretion provides a 
compensatory system of virtually infinite gain to oppose pro-
cesses causing elevation in BP, including increases in periph-
eral vascular resistance. It follows that in collectrin KO mice, 
even if the initial cause of hypertension is increased peripheral 
vascular resistance from reduced vasorelaxation, a defect in 
renal excretory function would be a prerequisite for the sus-
tained chronic increase in BP. The altered pressure natriure-
sis observed in collectrin KO mice suggests that the altered 
kidney function could result from a defect in renal epithelial 
function or renal hemodynamics. We found no alteration in 
the expression of renal epithelial sodium transporters or chan-
nels in the kidney in collectrin KO mice at baseline, but we 
cannot exclude improper localization of these transporters or 
channels. We postulate that the impaired pressure natriuresis 
is due, at least in part, to abnormal regulation of renal vas-
cular resistance,46 possibly caused by a deficiency in NO.47,48 
These possibilities will be a major focus in future studies. 
Collectrin is also expressed in the basolateral surface of the 
collecting duct epithelium (Zhang et al1 and our unpublished 
data), where neuronal NOS is localized and has been shown to 
be the source of NO that mediates medullary blood flow49 and 
natriuresis.50 Whether collectrin affects the dimerization and 
function of neuronal NOS in the collecting duct remains to be 
explored. Ultimately, it will be necessary to determine the pre-
cise cell lineage—in the kidney (and in which compartment: 
vascular versus proximal tubule, collecting duct epithelium, or 
both), outside the kidney, or both—in which BP is regulated 
by the actions of collectrin.
Conclusions
Our studies have unveiled collectrin as a determining fac-
tor in the development of hypertension in conditions in 
which the l-arginine/NO/O2∙ −  pathway is altered. Loss of 
collectrin function may also affect other physiological and 
pathophysiological states that are influenced by NO or super-
oxide signaling.
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CLINICAL PERSPECTIVE
Hypertension is a major risk factor for stroke, heart disease, and kidney disease. Although the causes of hypertension in 
most cases are not known, a defect in the balance of nitric oxide and superoxide, important regulators of vascular tone, may 
be a key initiating event. Our studies have unveiled a novel gene, collectrin, as a determining factor in the development of 
hypertension in conditions in which the balance of nitric oxide and superoxide may be altered. Collectrin may regulate 
blood pressure homeostasis through its role in regulating the transport of l-arginine, a substrate for nitric oxide generation, 
in endothelial cells. Through the identification of pathways regulated by collectrin to control blood pressure, novel insights 
and potential new opportunities for improving treatments of hypertension and its complications may be possible.
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SUPPLEMENTAL MATERIAL 
 
 
Supplemental Experimental Procedures 
 
 
Radiotelemetric blood pressure monitoring in vivo.  Briefly, mice were anesthetized with 2% 
isoflurane in medical oxygen (95% O2 and 5% CO2).  A catheter and sensor (TA11PA-C10, 
Data Sciences International (DSI), St. Paul, MN) was implanted in the left carotid artery, and the 
radiotransmitter was placed in a subcutaneous pouch along the flank.  A post-operative 
analgesic, buprenorphine, 0.1 mg/kg body weight, sc., and 0.25% bupivacaine, 0.02-0.05 
mg/kg, sc., was given to relieve pain.  Mice were allowed to recover for 7 days after surgery to 
regain their normal circadian rhythms before blood pressure measurements and experiments 
were initiated.  While blood pressure was being monitored, mice were housed in a quiet room in 
individual cages placed above the telemetric receivers with an output to a computer.     Blood 
pressures were collected every 1 hour for 5 minutes, processed, and analyzed using Dataquest 
A.R.T. 20 software (DSI).   
 
Urine studies.  Mice were housed individually in metabolic cages and urine was collected over 
a 24-hour period.  Urinary sodium was measured using flame photometer (IL-943, 
Instrumentation Laboratory, Lexington, MA).    Urinary 8-isoprostane F2 was measured using 
commercially available ELISA kit from Oxford Biomedical Research, Inc. (Oxford, MI, Product 
number: EA 85) and urinary nitrates/nitrites were measured using commercially available 
Colorimetric Assay kit from Cayman Chemical Company (Ann Arbor, MI, Product number 
780001), according to manufacturer’s instructions. 
 
Renal Ablation:  Under general anesthesia, (1.5 % isoflurane), the right kidney was removed 
(for both sub-total nephrectomy or uni-nephrectomy), and the blood supply of the upper half of 
 2 
the left kidney was interrupted by ligation of the upper branch of the two main branches of the 
left renal artery (for sub-total nephrectomy) as previously reported (1).   
 
Measurement of blood pressure using tail cuff manometry.   Blood pressures in mice 
subjected to nephrectomy were measured using a computerized tail cuff system (Hatteras 
Instruments, Cary NC) that determines tail blood flow using a photoelectric sensor.  This system 
allows for blood pressures to be measured in four mice simultaneously and minimizes the 
potential for observer bias.  Mice are trained for blood pressure measurement everyday for 2 
weeks, then systolic blood pressures are recorded daily for 2 weeks.   
 
Measurement of plasma renin concentration.  Plasma renin concentration was measured by 
radioimmunoassay of angiotensin I by use of the antibody-trapping technique (2).  Only results 
with linearity in 3 serial dilutions were accepted.  Renin values were standardized with renin 
standards obtained from the National Institutes for Biological Standards and Control (Potters 
Bar, Hertfordshire, UK) and are expressed in milliGoldblatt units per milliliter (mGU/ml). 
 
Tempol administration:  Tempol (4-hydroxy-Tempo, Aldridge-Sigma), was prepared in sterile 
saline and infused in mice using Alzet mini-osmotic pump, model 2004 (Durect Corporation, 
Cupertino, CA) at rate 200 nmol.kg-1.min-1 in a 28 day pump. Pump was implanted under the 
skin on the back of anesthetized mouse and wound was closed by surgical clips.  Mice were fed 
high salt diet beginning on day 10 after Tempol initiation. 
 
Endothelium-dependent and -independent relaxation assays.   Vasoreactivity 
measurements were performed as previously described (3).  Mice were sacrificed with CO2 and 
both thoracodorsal (TD) arteries and the whole mesentery were isolated and placed in Kreb’s 
Hepes solution or MOPS buffer respectively.  The TD and 3rd order mesenteric arteries were 
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free of surrounding tissue and cannulated at both ends on glass micropipettes, secured with a 
10-0 nylon monofilament suture in a pressure myograph (Danish MyoTechnology, DMT).  The 
TD and 3rd order mesenteric arteries were maintained at 37°C in a no-flow state and held at a 
constant transmural pressure of 80 mmHg and 75mmHg respectively (3-4).   TD arteries and 
mesenteric arteries were pre-constricted with phenylephrine (PE, 10 µM),  respectively and the 
internal diameter was measured in response to cumulative concentrations of Ach or SNP (10-9 
to 10-3 M).    Vessel diameter was quantified after each dose of Ach or SNP using the slide book 
software or the DMT vessel acquisition software as previously described (3, 5).   
 
 
Isolation of mouse pulmonary endothelial cells.  Primary lung endothelial cells were isolated 
as previously described (6).  Tissue culture reagents were from Invitrogen unless otherwise 
noted.  Lungs from 3 to 4 mice per group were first perfused with PBS containing 100 ug/ml 
heparin (Sigma) and 1% Anti-Anti and Pen/Strep (200 U/ml penicillin, 200 ug streptomycin, and 
25 ng Amphotericin B,), minced, and digested in PBS containing 100 ug/ml heparin, 1% Anti-
Anti and Pen/Strep, 0.1% collagenase (Sigma), and 5 mM CaCl2 at 37
oC for 30-60 min.  After 
filtration through a 100 um cell strainer (BD Falcon), the cells were pelleted at 500 xg for 10 min, 
resuspended and washed twice in DMEM low glucose with 20 mM HEPES and 1% Anti-Anti 
and Pen/Strep, then washed once in DMEM low glucose, 20 mM HEPES, 1% Anti-Anti and 
Pen/Strep, and 20% FBS. Finally, the cells were resuspended in 3 ml of Complete Media, 
(consisting of DMEM low glucose containing 20% FBS, 20 mM HEPES, 2 mM  each Glutamine 
and Sodium Pyruvate, 1% each Non-Essential amino acids, Anti-Anti, and Pen/Strep, 100 ug/ml 
each ECGS (endothelial cell growth supplement, BD Biosciences) and heparin, and 3.6 ug/ml 
thymidine), placed into one well of a 6 well plate, and incubated at 37oC in 95% O2 5% CO2, 
80% humidity. The red blood cells and other non-adherent cells were washed off after 1 day. 
The remaining cells were cultured in Complete Media with 10 ug/ml Dil-Ac-LDL (Biomedical 
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Technologies) for 3-4 hrs, then removed from the wells using Trypsin/EDTA and sorted by 
FACS. The positive cells were recovered and expanded in Complete Media in 6-well plates.    
  
Construction of collectrin over-expression vector.  Total RNA was extracted from whole 
mouse kidney tissue using TRIzol reagent (Invitrogen, NY, USA) and a spin-column purification 
kit (RNeasy Mini Kit; Qiagen, CA, USA) according to manufacturer protocols.  cDNA was then 
generated using the Bio-Rad iScript cDNA synthesis kit (Bio-Rad Laboratories, CA, USA) and 
was subsequently used as template for PCR.   5'- and 3'- PCR primers (Eurofins MWG Operon, 
AL, USA) were designed to amplify the collectrin cDNA and incorporate a 5'- NheI restriction site 
and a C-terminal  myc epitope tag and 3'-EcoRI restriction site.  The resultant PCR product was 
gel-purified (QIAquick Gel Extraction Kit; Qiagen, CA, USA), subjected to restriction enzyme 
digest (New England Biolabs, MA, USA) and cloned into the pBK-CMV expression vector 
(Stratagene, CA, USA) using standard techniques.   Purified mini-prep plasmid samples 
(QIAprep Miniprep Kit; Qiagen, CA, USA) were sequenced for verification (UAB DNA 
Sequencing Core Facility; Birmingham, AL, USA). 
 
Knockdown and over-expression of collectrin in primary human coronary endothelial 
cells.  Primary human coronary endothelial cells (HCECs) (Lonza Group Ltd., Switzerland) were 
grown in MCDB 131(GIBCO) supplemented with FBS, hydrocortisone, hFGF-B, VEGF, R3-IGF-
1, ascorbic acid, hEGF, GA-1000 (Lonza Group Ltd., Switzerland) and 1% L-glutamine (GIBCO) 
in 75-cm2 Corning tissue culture flasks at 37°C in a humidified environment of 5% CO2 and air. 
Cells were maintained at subconfluent level and passaged using trypsin/EDTA (GIBCO).   For 
siRNA studies, high-performance purity grade (>90% pure) small interfering RNAs (siRNAs) 
against collectrin (Collectrin-siRNA) and siRNAs with a nonsilencing oligonucleotide sequence 
(nonsilencing siRNA), used as a negative control (control-siRNA), were obtained from Ambion, 
Inc. Cells were seeded at a density of 3×104 cells per well in 6-well plates and grown in MCDB 
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131 with the additives. One day after seeding, cells were transfected with 20 umol of control- or  
collectrin-siRNA using siPORT NeoFX Transfection Agent (Ambion) per manufacturer’s 
instructions. Seventy-two hours post transfection, cells were harvested for Western 
immunoblotting.   For over-expression studies, 2 ug of plasmid DNA construct (PBK-CMV-
collectrin cDNA construct to overexpress collectrin and PBK-CMV empty vector for control) were 
transfected using Transfectin lipid reagent (BIO-RAD) into HCECs, seeded at a density of 3×104 
cells and grown in 6-well plates.  At 48 hours after transfection, the cells were harvested for 
Western immunoblotting and L-Arg uptake studies. 
 
Western immunoblotting.   Unless otherwise noted, tissues or cells were rapidly obtained and 
placed into ice-cold isolation buffer (10 mM Tris, 250 mM sucrose and 5 mM EDTA, pH 7.4) with 
protease inhibitor cocktail (Sigma-Aldrich).  Homogenates were then rapidly processed as 
described (7-8).  Briefly, tissues or cells were homogenized for 10 s and lysates were spun at 
3000 g for 10 minutes at 40C.  The supernatant was saved on ice, and the pellet was 
resuspended, homogenized and centrifuged.  The two supernatants were combined and spun at 
16,000 g for 30 minutes at 40C.   The resulting supernatant represented the intracellular fraction.  
Pellets were resuspended in isolation buffer and represented the plasma membrane fraction.  
Protein concentrations of each fraction were determined by the BCA assay (Bioassay Systems).  
Twenty µg of total protein was loaded onto 10% SDS-PAGE gels and then transferred to PVDF 
membranes (Invitrogen) per manufacturer instructions.  For eNOS, homogenization buffer  of 50 
mmol/l Tris·HCl, pH 7.6, 100 mmol/l NaCl, 2 mmol/l EDTA, 2 mmol/l EGTA, 1 mmol/l DTT, 1 
mmol/l PMSF, 1% Triton X-100, and 6% SDS-PAGE gels and nitrocellulose membrane were 
used.  Membranes were blocked using Blocking Solution (Invitrogen) for 1 hr at room 
temperature.  Membranes were then incubated at 40C overnight with primary antibody diluted in 
blocking buffer as follows: rabbit anti-collectrin antibody (1:1000) (custom made for Le’s lab by 
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Covance Immno Technologies, Denver, PA) by generation against the synthetic peptide 
(NDAFMTEDERLTPL) as previously reported  (9), rabbit anti-eNOS (BD Biosciences) at 1:1000, 
anti-CAT1 antibody (Santa Cruz Biotechnology) at 1:1000, anti-y+LAT1 antibody (Santa Cruz 
Biotechnology) at 1:1000, anti-y+LAT2 (Santa Cruz Biotechnology) antibody at 1:1000, mouse 
anti-tubulin at 1:2000 (Santa Cruz).  Antibody to ENaC (at 1:500) was a kind gift from Dr. 
Susan Wall (Emory University) and antibodies to NHE3, NKCC, Na-K-ATPase, and NaPi2 (at 
1:1000) were kind gifts from Dr. Mark Knepper (National Institute of Health) (10-11).  Secondary 
antibody incubation was performed for 30 minutes at room temperature with anti-rabbit and anti-
mouse conjugated with alkaline phosphatase.  Blots were visualized using WesternBreeze 
chemiluminescent detection kit (Invitrogen). 
 
Immunohistochemical and immunofluorescence studies.   Chromogenic 
immunohistochemical staining for collectrin was done on paraffin-embedded, formalin-fixed 4 
µm cross-sections of kidney and thoracodorsal artery from WT mice using the Dako EnVision+ 
System-HRP (DAB) Kit, (using Rabbit anti Collectrin Ab), and the Dako Mayer’s Hematoxylin 
Histological Staining Reagent (Dako North America, Inc.) according to the manufacturer’s 
instructions.  In short, the tissue was re-hydrated and antigens were unmasked using Antigen 
Unmasking Solution (low pH) (Vector Laboratories, Inc.) by heating in a microwave oven.  
Incubation was for 40 min at room temperature for the primary collectrin antibody (1:500), then 
the peroxidase labeled polymer; 10 min at room temperature for the DAB+ Chromogen; and 1-2 
min with the Hematoxylin counterstain. The tissue sections were covered with coverslips, and 
sealed with VectiShield Hard Mount (Vector Laboratories, Inc.).    Immunoflourescent staining 
was performed on paraffin-embedded, formalin-fixed 4 µm cross-sections of kidney from wild-
type mice that were obtained using a microtome (RM2125, Leica Microsystems Inc., 
Bannockburn, IL).  The sections were re-hydrated and antigen retrieved with microwave heat for 
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15 min in TEG buffer (10mM Tris and 0.5mM EGTA, pH 9.0).  After neutralization with NH4Cl 
buffer, the sections were blocked with 1% BSA, 0.2% gelatin, and 0.05% saponin in PBS before 
incubation overnight with primary antibody diluted in 0.1% BSA and 0.3% Triton X-100 in PBS.  
The primary antibody against collectrin was obtained as described above, and against CD105 
(Biolegend) specific for endothelial cells).  After rinsing with 0.1% BSA, 0.2% gelatin, and 0.05% 
saponin in PBS, the sections were reacted 1 hr with secondary antibody diluted in 0.1% BSA 
and 0.3% Triton X-100 in PBS.  The secondary donkey anti-rabbit antibodies used were 
Alexa555- or Alexa647-conjugated (Invitrogen Corp., Carlsbad, CA).  After washes with PBS, 
the sections were mounted in Vectashield solution containing DAPI to stain nuclei (H-1500, 
Vector Labs., Burlingame, CA).  Confocal fluorescence images were taken using a Zeiss LSM 
510 microscope and software (Carl Zeiss MicroImaging, Inc., Thornwood, NY). 
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Supplemental Figure Legends. 
 
Supplemental Figure 1. Comparison of SBP and MAP of Collectrin KO and WT mice. (A) KO 
mice have normal diurnal variation during 12 hrs light and dark cycles. (B) MAP of KO mice are 
significantly elevated during both light and dark cycles; Light:  WT 111.1  1.4, KO 117.6  1.3 
mm Hg, p = 0.002, Dark:  WT 122.0  1.6, KO 128.1  1.4 mm Hg, p = 0.007, n = 6 each. (C) 
Correlation of SBP and heart weight/body weight ratio, R2 = 42%, p = 0.003. Data points are 
from both WT and KO mice.  (D)  Immunoblot of plasma membrane fractions of whole kidney 
homogenates demonstrating that renal epithelial salt transporters or channels such as NKCC, 
NHE3, Na-K-ATPase, α-ENaC and NaPi2 transporters are not altered in collectrin-KO mice at 
baseline.  Tubulin is loading control. Densities, normalized to tubulin, were not statistically 
significant. (E) Baseline plasma renin concentration, expressed as x 10-5 Goldblat Unit (GU)/mL.  
WT 575  172 vs KO 404  81 x 10-5 GU/mL, n  6, p = 0.40. (F) By real-time RT-PCR, baseline 
mRNA levels of ACE2 and mas receptor in the renal cortex are not different between wild-type 
and collectrin KO mice.   
 
Supplemental Figure 2. (A) Survival rate of Collectrin KO and WT mice after sub-total 
nephrectomy, performed by removing the right kidney and ligating the arterial supply of the 
upper half of the left kidney.  In the WT group, there is 100% (10 out of 10) survival on day 21. 
In KO group, 4 out of 7 mice died by day 21, giving a survival rate 43%; p<1x10-6. (B) SBP of 
collectrin KO mice is significantly increased after uni-nephrectomy compared to WT mice (WT 
151 ± 2, n=9; KO 165 ± 2 mm Hg, n=7, p=0.0007). 
 
Supplemental Figure 3. Expression of collectrin in vasculature. (A) Upper, immunoblot of 
collectrin protein in 3 out of 3 separate pure EC lines isolated from pulmonary artery of WT mice. 
Lower, immunoblot showing collectrin protein is expressed in the aortas from 6 WT mice. (B) 
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Confocal microscopy of the renal vasculature: red - antibody for collectrin, blue - CD105 
antibody specific for ECs, fuchsia – merged pannels. Upper, the large renal vessels. Bottom, the 
sinus/inner stripe of the renal medulla where vascular bundles and capillar plexuses are found.  
 
Supplemental Figure 4.  Immunoblot of y+LAT1 transporter in plasma membrane fractions 
from whole kidney with tubulin as a loading control. N = 3 mice in each group.  By densitometry, 
KO kidney PM fractions express significantly less y+LAT1, p = 0.01. 
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Supplemental Figure 1A   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1B  
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Supplemental Figure 1C  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1D            
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Supplemental Figure 1E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1F 
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Supplemental Figure 2A   
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Supplemental Figure 3A 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 3B 
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Supplemental Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y+LAT1
Tubulin
WT KO
